

January 2018



UPCOMING MEETINGS

Jan 25: Regulation of Clinical Research Related to HIV Cure Conference; Bethesda, MD

Feb 21-22: HVTN 2018 Regional Meeting; Cape Town, South Africa

Mar 4-7: CROI 2018; Boston, MA

Mar 18-21: 2018 MTN Annual Meeting; Bethesda, MD

May 14-16: HVTN Annual Meeting; Washington, DC

May 17-19: HPTN Annual Meeting; Washington, DC

June 8-10: Adherence 2018; Miami, FL

June 16-19: IMPAACT Annual Meeting, Washington, DC

Jun 20-24: 2018 Annual ACTG Network Meeting; Washington, DC

Jul 23-27: 22nd International AIDS Conference, Amsterdam, the Netherlands

Oct 22-25: HIVR4P 2018; Madrid, Spain

For details on these and other events, go to the [HANC calendar](#).

FOLLOW US ON 

 Find us on Facebook

www.hanc.info

1100 Eastlake Ave E.
Seattle WA USA 98109

HANC & Network Announcements

HANC: HANC recently hired a new Project Coordinator, Milan Vu. A local to the Seattle area, Milan comes with a background in public health and research. She holds a Bachelor of Science degree in Biology from the University of Washington, and previously worked for the Centers for Disease Control and Prevention as an assignee to the North Dakota Department of Health in Bismarck, ND. There, her experiences included coalition facilitation, program operations, and community health initiatives. Milan will assist HANC Project Manager, Cale Reid, in facilitating all HANC Cross-Network Coordination-related working groups.



ACTG recently released its latest [newsletter](#). In this edition, you'll find out more about:

- ACTG's Network Chair and PI, Dr. Judith Currier shares her outlook for 2018.
- The University of Colorado site celebrates 25 years of HIV/AIDS treatment progress.
- And information about 2018 National HIV/AIDS Awareness Days.



The HIV Prevention Trials Network (HPTN) recently announced the initiation of [HPTN 084](#), a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC). The study is the first large-scale clinical trial of a long-acting injectable medication for HIV prevention in sexually active women. If found to be safe and effective for HIV pre-exposure prophylaxis (PrEP), injectable CAB may be an easier, more desirable, discreet alternative to daily oral TDF/FTC for some women.



HIV VACCINE TRIALS NETWORK

The HIV Vaccine Trials Network (HVTN) and its partners will gather for the **2018 Sub-Saharan Africa Regional Meeting** 21 & 22 February at The Westin Cape Town. Currently in a busy and productive time, network partners will gather to consider advances in the conduct of landmark trials evaluating bnAbs and vaccines, while con-

sidering the robust HIV prevention research agenda in the region. Months of site development and personnel training have provided added capacity for clinical trials implementation in the region. Representatives from all of our African sites will gather to consider how the HVTN's clinical trials portfolio will continue to be responsive to new data and changing standards of prevention, and suggestions for clinical trial design among other topics. Protocol teams will hold training sessions and operations discussions for participating sites. For details on our most recently launched efficacy trial, HVTN 705/HPX2008, please [click here](#) or visit the [study website](#).



A Phase III, three-arm, randomized, open-label study to evaluate newer antiretroviral therapy regimens among pregnant woman and their infants opened to accrual. This study (IMPAACT 2010) will compare the safety and virologic efficacy of maternal EFV/FTC/TDF with regimens containing dolutegravir (DTG) and either tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF). Over 500 mother-infant pairs are expected to be enrolled at sites in Botswana, Brazil, Haiti, India, Malawi, South Africa, Thailand, Uganda, the United States, Tanzania, and Zimbabwe.



MTN is pleased to announce that the Bangkok, Thailand site for [MTN-026](#), the first-ever study of dapivirine gel as a rectal microbicide, has been activated. The Silom Community Clinic Clinical Research Site joins previously launched MTN-026 sites in the U.S. in Pittsburgh, Pennsylvania and Birmingham, Alabama.

Attending the upcoming NAESM 2018 meeting in Atlanta? MTN researchers will be presenting, Flirt, Squirt & Insert: Developing rectal microbicides for YOUR sex life from noon-1:30 p.m., Friday, January 19. The workshop will explore where rectal microbicide research is heading and why it is vitally needed. Panelists will address the development of rectal microbicides that incorporate common anal sex practices (like douching or use of a lube) and those that could help to enhance the sexual experience.

January 2018



REMINDERS

- The “[Portal Trainings & FAQ](#)” pages and documents have been updated for SharePoint 2010.
- Have you ever wondered how to reach a colleague at another network or DAIDS? Check out the [cross-network contact list](#), the [DAIDS staff list](#), or the [DAIDS Topic-specific contact list](#) on the left-hand navigation bar of the [portal homepage](#).
- **Did you know?** NIAID posts funding opportunities to its public website. For more details, [click here](#).
- Check out the [NIH Clinical Regulation website](#), created with the goal of helping researchers learn about international clinical regulations. Users can compare clinical regulations between countries in navigable side-by-side format, in topics such as Ethics Committees, Sponsorship, Clinical Trial Lifecycle, and more!
- Did you know you can access real time accrual information and protocol documents on the HANC portal? [Click here to go to the Quick Protocol Summary!](#)

HELPFUL TIPS

- Forgot your portal password? Reset it by going to [Log On Help](#).
- Find many HIV/AIDS [resources and links](#) www.hanc.info.

FOLLOW US ON 



www.hanc.info

1100 Eastlake Ave E.
Seattle WA USA 98109

HANC Program Highlights

Behavioral Science: The Behavioral Science Consultative Group will hold a call later this month. The group will continue to discuss the [AMP Study](#), the [PHOENIX Study](#), [HPTN 083](#), [HPTN 084](#), and [MTN 034](#). The BSCG will also start discussing the agenda for the upcoming face-to-face meeting in June 2018.

Community Coordination: Community Partners is in the process of nominations for a Strategic Working Group (SWG) representative. SWG representatives serve to provide a direct link between Community Partners and Network leadership. SWG representatives bring a cross-Network community perspective into leadership discussions.

Data Management Center (DMC): The Data Management Center Working Group discussed implementation of the new DAIDS Safety Data Reconciliation Policy with representatives from OPCRO and the DAIDS RSC.

Laboratory: The Laboratory Focus Group discussed updating the Cross-Network Guidelines for Diagnosis of HIV Infection as well as the Cross-Network PBMC Processing SOP. The LFG is also currently electing a new Co-Chair to serve alongside the current Co-Chair, Estelle Piwowar-Manning. The TB Lab Diagnostics Working Group discussed efforts of the TBQA Advisory Group as well as shared updates about the development of the HANC TB infection control training module.

Legacy Project: January 17-21: Legacy staff will be in Atlanta, GA for the 2018 NAESM Conference, where they are involved with the following activities:

- Thursday, January 18, 2:15 to 5 PM: “Getting Your HIV Science Fleeky: A Research Literacy Workshop” (Louis Shackel-

ford and Brian Minalga in partnership with the HPTN, HVTN, and MTN).

- Friday, January 19, 3:30 to 5 PM: “T Cells & Jail Cells: HIV Research & Criminalization” (Brian Minalga)
- Saturday, January 20, 10:15 to 11:45 AM: “Black and Latino MSM: Partnerships to Address HIV” (Louis Shackelford)

Legacy staff is in the process of updating the BTG HIV Prevention Research Module, which covers HIV/AIDS science and history, the clinical research process, community engagement, and the combination HIV prevention toolbox including microbicides, PrEP, TasP, and vaccines. The update will be complete in early 2018; Legacy will make the module available at that time.

The Women’s HIV Research Collaborative, in partnership with Treatment Action Group, the Elizabeth Glaser Pediatric AIDS Foundation, and the Society for Maternal Fetal Medicine, is planning a webinar series on the inclusion of pregnant and breastfeeding women in biomedical research to take place in February and March. More information will follow in next month’s newsletter.

Network Working Group/Pilot 2 Working Group:

The Network and Pilot 2 Working Groups are working to develop their final recommendations related to harmonizing the distribution of protocol funds and protocol costing methodologies across the networks. Recommendations will be submitted to DAIDS in January 2018.

Youth Prevention Research Working Group: The Youth Prevention Research Working Group has submitted a proposal to host a satellite symposium at [AIDS 2018](#). The YPRWG held a satellite session at IAS 2017 that was well attended and received. The current proposal would provide an update from the session at IAS 2017 where the YPRWG discussed [HPTN 082](#), [MTN 034](#), [IMPACT 2009](#), and ATN’s [iTech study](#).